Henderson, Nevada, October 27, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent (“LOI”) with Missionpharma A/S, a Danish global leader in the sale and distribution of healthcare products and innovative solutions, impacting the lives of over 100 million patients annually, regarding the potential development and launch of Volition’s prototype Lateral Flow Technology (“LFT”) for NETosis.
Dr. Gaetan Michel, Chief Operating Officer, Volition commented:
“We recently announced a major technical milestone: results utilizing our lateral flow prototype are highly correlated with results utilizing Volition’s established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing. This finger prick sample test could be used worldwide, beyond solely high-income countries.
“The Nu.Q® NETs test quantifies circulating nucleosomes and Neutrophil Extracellular Traps (NETs) as early indicators of hyper-inflammation, and we believe its use will cover a broad range of diseases including sepsis and septic shock.
“By enabling decentralized testing, our total addressable market expands, and, with the help of Missionpharma, we hope to accelerate commercialization and market access, particularly in resource-constrained countries and humanitarian emergency settings.”
Agustin Travaini, Director, Strategic Partnerships, UN, Missionpharma commented:
“At Missionpharma, we are proud to have strong partnerships with a broad institutional base, including United Nations (“UN”) agencies specialized in global health and humanitarian response.
“We aim to explore opportunities to closely work with Volition in the introduction, development, and scale-up of its LFT test for NETosis, potentially assisting with low-cost manufacturing, clinical studies, and distribution.
“We see a very strong interest from our partners and customers in Volition’s innovative diagnostic solutions, particularly in low- and middle-income countries (“LMICs”) and humanitarian emergency settings, and are excited to collaborate with the aim of saving millions of children’s lives annually.”
Dr Andrew Retter, Medical Consultant, Volition said:
“The proprietary Nu.Q® technology, including Volition’s finger-prick lateral flow prototype, has broad clinical utility.
“Following on from discussions with key global health institutions, it is clear that Volition’s clinical intended use should initially focus on one well defined use: developing and validating a tool for triaging and prognostication for neonatal sepsis (sepsis in newborns and young infants).
“An estimated 2.3 million newborns die each year2. Sepsis is a major contributor in settings such as LMICs, especially in Africa, which bears the greatest mortality burden. Severe infections are among the major causes of newborn deaths. Studies have shown that 84% of these deaths could be spared if an early diagnosis and patient management tools were available3.
“The Nu.Q® NETs LFT prototype test is a potential gamechanger. We are delighted that Volition and Missionpharma have now established a basis for collaboration with initial focus on evaluating the lateral flow prototype with a well-defined and impactful first clinical utility, sepsis in newborns and young infants.
“We look forward to continuing our work together with Missionpharma.”
- Data on File, Volition
- The United Nations Inter-agency Group for Child Mortality Estimation. Levels and trends in child mortality: Report 2025 (accessed Sept 2026)
- Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization; 2020 Report (accessed Sept 2026)
About Missionpharma
Missionpharma is a global leader in the sale and distribution of healthcare products and innovative solutions, supplying UN agencies, international and local non-governmental development organizations, and public and private sector institutions, including the WHO and Ministries of Health across LMICs.
Since 1975 Missionpharma has contributed to improving global health by supplying quality medicines, medical devices, and health kits to people all over the world, every year improving the lives of more than 100 million people.
Since 2012, Missionpharma has been a proud member of CFAO Healthcare, the healthcare division of CFAO Group, owned by Toyota Tsusho Corporation.
